

# Fostamatinib

Immunthrombozytopenie (ITP) » rezidiert/refraktär

Empfehlungen der Fachgesellschaft zum Einsatz neuer Arzneimittel

## **Herausgeber**

DGHO Deutsche Gesellschaft für Hämatologie und  
Medizinische Onkologie e.V.  
Bauhofstr. 12  
10117 Berlin

Geschäftsführender Vorsitzender: Prof. Dr. med. Andreas Hochhaus

Telefon: +49 (0)30 27 87 60 89 - 0

[info@dgho.de](mailto:info@dgho.de)

[www.dgho.de](http://www.dgho.de)

## **Ansprechpartner**

Prof. Dr. med. Bernhard Wörmann  
Medizinischer Leiter

## **Quelle**

[www.onkopedia.com](http://www.onkopedia.com)

Die Empfehlungen der DGHO für die Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen entbinden die verantwortliche Ärztin / den verantwortlichen Arzt nicht davon, notwendige Diagnostik, Indikationen, Kontraindikationen und Dosierungen im Einzelfall zu überprüfen! Die DGHO übernimmt für Empfehlungen keine Gewähr.

# Inhaltsverzeichnis

<b>1 Fostamatinib, ITP, relapsed/refractory .....</b>	<b>2</b>
---	----------

# Fostamatinib

**Dokument:** Fact Sheet

**Spezifizierung:** Immunthrombozytopenie (ITP) » rezidiert/refraktär

**Stand:** November 2020

## 1 Fostamatinib, ITP, relapsed/refractory

### Fostamatinib, ITP, relapsed/refractory

onkopedia				Facts	Appraisal																																																																																
<b>Parameter</b>	<b>Results</b> <sup>14</sup>	<b>HR</b> <sup>15</sup>	<b>p value</b>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 10%;"></td><td style="width: 10%;"></td><td style="width: 10%;"></td><td style="width: 10%;"></td><td style="width: 10%;"></td><td style="width: 10%;"></td><td style="width: 10%;"></td><td style="width: 10%;"></td><td style="width: 10%;"></td><td style="width: 10%;"></td> </tr> <tr> <td style="text-align: center;">5</td><td style="text-align: center;">4</td><td style="text-align: center;">3b</td><td style="text-align: center;">3a</td><td style="text-align: center;">2c</td><td style="text-align: center;">2b</td><td style="text-align: center;">2a</td><td style="text-align: center;">1b</td><td style="text-align: center;">1a</td><td style="text-align: center;"></td> </tr> <tr> <td colspan="10">Evidence (LoE)</td> </tr> <tr> <td colspan="10" style="height: 15px;"></td> </tr> <tr> <td colspan="10">Clinical benefit (ESMO MCBS)</td> </tr> <tr> <td colspan="10" style="text-align: center;"> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%;"></td><td style="width: 20%;"></td><td style="width: 20%;"></td><td style="width: 20%;"></td><td style="width: 20%;"></td> </tr> <tr> <td style="text-align: center;">1</td><td style="text-align: center;">2</td><td style="text-align: center;">3</td><td style="text-align: center;">4</td><td style="text-align: center;">5</td> </tr> </table> </td> </tr> <tr> <td colspan="10" style="text-align: center;"> <span style="color: blue;">■</span> curative    <span style="color: yellow;">■</span> non-curative                 </td> </tr> </table>												5	4	3b	3a	2c	2b	2a	1b	1a		Evidence (LoE)																				Clinical benefit (ESMO MCBS)										<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%;"></td><td style="width: 20%;"></td><td style="width: 20%;"></td><td style="width: 20%;"></td><td style="width: 20%;"></td> </tr> <tr> <td style="text-align: center;">1</td><td style="text-align: center;">2</td><td style="text-align: center;">3</td><td style="text-align: center;">4</td><td style="text-align: center;">5</td> </tr> </table>															1	2	3	4	5	<span style="color: blue;">■</span> curative <span style="color: yellow;">■</span> non-curative									
5	4	3b	3a			2c	2b	2a	1b	1a																																																																											
Evidence (LoE)																																																																																					
Clinical benefit (ESMO MCBS)																																																																																					
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%;"></td><td style="width: 20%;"></td><td style="width: 20%;"></td><td style="width: 20%;"></td><td style="width: 20%;"></td> </tr> <tr> <td style="text-align: center;">1</td><td style="text-align: center;">2</td><td style="text-align: center;">3</td><td style="text-align: center;">4</td><td style="text-align: center;">5</td> </tr> </table>															1	2	3	4	5																																																																		
1	2	3	4	5																																																																																	
<span style="color: blue;">■</span> curative <span style="color: yellow;">■</span> non-curative																																																																																					
<b>SAE</b> <sup>7</sup>	15 vs 16		n.s. <sup>16</sup>																																																																																		
<b>SR</b> <sup>11</sup>	2 <sup>19</sup> vs 18 <sup>19</sup>		p = 0.0003																																																																																		
<b>OR</b> <sup>12</sup>	14 <sup>20</sup> vs 43 <sup>20</sup>		p = 0.0006																																																																																		
<b>Patients</b>	relapsed / refractory																																																																																				
<b>Trial</b>	Phase 3																																																																																				
<b>Randomisation</b>	2 : 1																																																																																				
<b>N</b> <sup>1</sup>	150																																																																																				
<b>New Therapy</b>	Fostamatinib																																																																																				
<b>Control</b>	Standard of Care																																																																																				
<b>Publication</b>	DOI:10.1002/ajh.25125																																																																																				

Legende:

<sup>1</sup> N - number of patients

<sup>7</sup> SAE - serious adverse events, CTCAE grade 3/4

<sup>11</sup> SR - sustained response

<sup>12</sup> OR - overall response

<sup>14</sup> results for control, results for new therapy

<sup>15</sup> hazard ratio for new therapy

<sup>16</sup> n. s. not significant

<sup>19</sup> platelets  $\geq 50 \times 10^9/L$  on 4 of 6 visits between week 14 and 24

<sup>20</sup> platelets  $\geq 50 \times 10^9/L$  within 12 weeks